Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NextWave Pharmaceuticals Inc.

Division of Pfizer Inc.
www.nextwavepharma.com

Latest From NextWave Pharmaceuticals Inc.

F-Prime Plays The Long Game In Health Care Investing

With strong backing, F-Prime Capital Partners can make large, high-risk bets around the world — and keep doubling down. An interview with F-Prime Managing Partner Stephen Knight.

BioPharmaceutical

Deals Of The Week: Big Pharmas Hoard Cash, But Aren’t Buying Yet In 2013

DOTW digs into a Moody’s report detailing which companies’ balance sheets have the most cash, even if the pharmas that made the cut haven’t been putting their purchasing power to work. In addition, details on Valeant’s latest dermatology acquisition, Merck’s deal with Cerecor for a portfolio of COMT assets, Janssen’s European cancer research tie-up, and an NPS/Takeda deal for orphan drugs.

BioPharmaceutical United States

Pharmas Among Biggest Cash Hoarders, Moody’s Finds

A Moody’s report lists seven pharmas among the 50 non-financial companies sitting on the largest piles of cash. These very big war chests hold the preferred currency, particularly for ex-U.S.pharma deal-making.

BioPharmaceutical United States

Biopharma Dealmaking Quarterly Statistics, Q4 2012

At $4.2 billion, biopharma financing in Q4 2012 showed a 36% increase over Q3 with FOPOs again dominating as the most popular deal type. With 34 finalized biopharma M&As, Q4 was the most active quarter of all 2012 for acquisitions. The 108 biopharma alliances completed had a combined potential deal value of almost $2 billion; Johnson & Johnson, with seven tie-ups, was the busiest pharmaco during Q4.

BioPharmaceutical Deals
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Drug Delivery
      • Controlled Release
    • Specialty Pharmaceuticals
  • Therapeutic Areas
  • Cardiovascular
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Pfizer Inc.
  • Senior Management
  • Jay P Shepard, Pres. & CEO
    Cynthia M Butitta, SVP, CFO
    Craig Chambliss, SVP, Chief Business Officer
    Sally A Berry, MD, PhD, Medical Advisor
    Tracy Woody, VP, Sales & Mktg.
  • Contact Info
  • NextWave Pharmaceuticals Inc.
    Phone: (408) 342-1300
    20450 Stevens Creek Blvd.
    Ste. 150
    Cupertino, CA 95014
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register